Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version - Siteman Cancer Center
Multimedia Signal Processing
Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18–65 years: NILG ALL 10/07
Udo BODE, University of Bonn, Bonn, Uni Bonn
Prospective use of molecular minimal residual disease for risk stratification in children and adolescents with acute lymphoblastic leukemia
PDF] Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.
PDF) Risk-adjusted therapy of acute lymphoblastic leukemia can
Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90 - ScienceDirect
Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf
Richard RATEI, Head of Department
High-Risk Pediatric Acute Lymphoblastic Leukemia: To Transplant or Not to Transplant? - Biology of Blood and Marrow Transplantation
Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group.
Figure 1 from Risk-adjusted therapy of acute lymphoblastic
Frontiers Model-Based Simulation of Maintenance Therapy of Childhood Acute Lymphoblastic Leukemia
